Skip to main content

Most Popular

FDA: New Cardiac and Cancer Warnings for All JAK Inhibitors

Sep 01, 2021

Today, Sept.1st, the FDA announced its findings regarding tofacitinib's safety concerns from the Oral Surveillance study - handing down warnings for not only Pfizer's JAK inhibitor, but also for other marketed JAK inhibitors from AbbVie and Eli Lilly & Co.

Read Article

ACR Comments on JAK Inhibitors and FDA Announcement

ACR
Sep 13, 2021

Statement from ACR President David Karp, MD, PhD:

Read Article

My Personal Delta COVID-19 Breakthrough Infection

As many of you are aware, I have written and spoken on COVID-19 extensively over these past 20 months, and just last month wrote about the dangers of the delta variant. In July, things took an unexpected turn when I developed a breakthrough infection with the delta variant.

Read Article

11 Drugs That Cause Arthritis

Sep 23, 2021

This is the #1 question I get from new consults: “How did I get arthritis?”

But as aching patients ask this question, they are really thinking these joint complaints must be due to:

Read Article

COVID Breakthrough Infections in Rheumatic Patients

Sep 08, 2021

Analysis of records from the Mass General Brigham healthcare system in the Boston area, shows that breakthrough infections (after receiving SARS-CoV-2 vaccines) in patients with systemic autoimmune rheumatic diseases (SARDs) are not uncommon, and may be severe or fatal.

Read Article

RheumNow Podcast – JAK Inhibitor Warnings from the FDA

Sep 02, 2021

Dr Jack Cush reviews the news, journal articles and FDA warnings from the past week on RheumNow.com

Read Article

Drug Choices After First TNF Inhibitor in RA

Aug 30, 2021

Tumor necrosis factor inhibitors (TNFi) are frequently used first line in rheumatoid arthritis (RA) patients; and a new analysis shows that repeat use of TNFi dominates over the use of non-TNFi biologics when the initial TNFi therapy has failed.

Read Article

ICYMI: The Greatest Rheumatologist - Part I

Sep 06, 2021

Who is the greatest rheumatologist? What makes for a great rheum?

Is it clinical acumen, scientific achievement, educational prowess or years of unrivaled service or mentoring?

Read Article

Predictors of Inflammatory Arthritis

Aug 31, 2021

Data from 4 parallel case-control studies within The Health Improvement Network looked at risk factors for developing psoriatic arthritis (PsA), psoriasis, rheumatoid arthritis (RA), and ankylosing spondylitis (AS) showed both shared and differentiating risk factors, but statin use was protective

Read Article

High Drug Switching and Low Persistence in Rheumatoid Arthritis

Sep 13, 2021

Mease and colleagues have catalogued the current practices assessed in the CORRONA registry, noting that increased DMARD switching and decreased time on a given therapy by US physicians.

Read Article

Not All Immunosuppression Alters Vaccine Immunogenicity

Sep 02, 2021

Chronic inflammatory disease (CID) patients are urged to receive the COVID-19 vaccines; but when a cohort of CID patients treated with immunosuppressive medications were given an mRNA-based SARS-CoV-2 vaccination, only those treated with glucocorticoids and B cell depleting therapies (BCDT) had l

Read Article

RheumNow Podcast – High Science and Future Treatments (9.10.2021)

Sep 10, 2021

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com

Read Article

Tocilizumab and Drug Shortage Headaches

Sep 22, 2021

Do you know what’s in short supply? Trust, pediatric rheumatologists, and drugs. Since the onset of the pandemic, numerous drug shortages have affected rheumatology, including sulfasalazine, hydroxychloroquine, and now, tocilizumab.

Read Article

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Dr. Jack Cush reviews the news and journal reports and takes cases and questions from rheumatologists.

Read Article

ICYMI: The Greatest Rheumatologist - Part II

Sep 06, 2021

Wow! I hope you read part I of yesterday's “Greatest Rheumatologist” article.  So many big names and yet, other names and stories that were equally inspirational.

If you read the comments of the part I article you can clearly see several themes emerge.

Read Article

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article

Interview Season

Sep 20, 2021

Rheumatology has become a highly competitive field, attracting the brightest and the best of internists, aspiring to careers in rheumatology. The skills of a rheumatologist include: curiosity, cognitive reasoning, diagnostic acumen, and love for exploration; with a degree of skepticism. 

Read Article

Guselkumab Treats Axial Disease in Psoriatic Arthritis

Sep 23, 2021

Pooled analysis of the DISCOVER-1 and DISCOVER-2 trials have shown that guselkumab, an IL-23 inhibitor, was effective and safe in psoriatic arthritis (PsA) patients with axial involvement and imaging-confirmed sacroiliitis.

Read Article

Risk Factors Associated with Systemic Sclerosis Hospitalization

Sep 09, 2021

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.

Read Article
×